AI is rewriting alliances. We wrote the code.
Shared facts for every partnership decision.
Human judgement. Machine speed.
Why it matters
-
$2.2bn
average spent by the top 20 pharma companies to bring one asset to launch
-
40%
of assets in-licensed by big pharma in 2025 came from Chinese biotechs
-
532
days, the median wait in Europe for a newly authorised medicine to reach patients
-
~20%
average M&A cost saving reported by dealmakers using generative AI
Behind every one of these figures is a medicine that reaches patients later, or a launch that falls short.
The Alliance Integrator
Agentic AI for partnerships, from asset scouting to patient.
Patent pending, shown under NDA.
-
Large pharma
Visibility from search and evaluation to the alliance portfolio.
Critical selection factors and show‑stoppers at screening, market access and pricing at valuation, every term in force once the alliance runs.
-
Scale-ups
Equal footing with big pharma partners.
The whole alliance portfolio in one record, so a lean team holds its ground at every steering committee.
-
Small companies and start-ups
A ready-built framework for alliances.
It guides the team step by step, from creating the alliance to managing it.
- Has hypercare become your new normal?
- How close to litigation is your alliance?
- Are you micromanaging your partner?
- Can you see into your secondary alliances?
- Which of your alliances is failing right now?
Advisory
Every engagement is a defined service contract with clear scope and deliverables.
Alliance management
Governance, obligations and steering committees run on one shared record, with the Alliance Integrator behind every decision. Nearly two decades of senior alliance management in large pharma and biotech, across Europe and emerging markets.
Recovery
Alliance failing? AI builds the fact base. We lead the recovery, with your counsel.
Build
New alliances start on shared facts. We set up the governance, the joint steering committee and the record of obligations before the first milestone.
Areas of expertise
From molecule scouting to patient.
Deal making
Business development and licensing, molecule scouting, valuation and due diligence, so an asset is valued with the consequences it carries.
Agentic AI
Architecture and orchestration, predictive and scenario analysis, AI enablement for in-house teams, and the Alliance Integrator, patent pending.
Alliance management
Governance, contract execution, early detection of breaches, litigation and exit scenarios, so a breach is seen when it happens.
Operations and launch
TechOps, quality and commercial operations, CRO and CMO partnerships, technology transfer, supply chain, distribution and product launch, from molecule to patient.
Perspectives
Read before your next deal.
Industry evidence on life sciences partnerships and valuation, with the founder’s view on what it means now.
Start a conversation
Book a consultation, or register for an Integrator demo. Your request comes straight to us.
Book a call opens Cal.eu, which has its own privacy notice.